Relative adrenal insufficiency in etomidate-Naïve patients with septic shock

Anaesthesia and Intensive Care

Volumn 34, Issue 5, 2006, Pages 599-605

  Jones, D ^a   Hayes, M ^b   Webb, S ^c   French, C ^d   Bellomo, Rinaldo ^e  

^a MONASH UNIVERSITY   (Australia)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d WESTERN HOSPITAL   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

Adrenal insufficiency; Etomidate; Hydrocortisone; Sepsis; Septic shock; Synacthen

Indexed keywords

ADRENALIN; DOPAMINE; ETOMIDATE; HYDROCORTISONE; HYPERTENSIVE FACTOR; INOTROPIC AGENT; NORADRENALIN; TETRACOSACTIDE;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ADULT; ARTICLE; ARTIFICIAL VENTILATION; AUSTRALIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK;

EID: 33750613028     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0603400506     Document Type: Article

References (21)

1. Kenyon N. Defining adrenal insufficiency in septic shock. Crit Care Med 2003; 31:321-323.
2. Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:2157-2159.
3. Annane D. Time for a consensus definition of corticosteroid insufficiency in critically ill patients. Crit Care Med 2003; 31:1868-1869.
4. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 31:141-145.
5. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348:727-734.
6. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
7. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536-555.
8. Opal SM. Corticosteroids for patients with septic shock. JAMA 2003; 289:41-42.
9. Abraham E, Evans T. Corticosteroids and septic shock. JAMA 2002; 288:886-887.
10. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24h after a single dose of etomidate. Anaesthesia 1999; 54:861-867.
11. Annane D. Author reply. JAMA 2003; 289:41, 43-44.
12. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 Jun; 20:864-874.
13. Malerba G, Romano-Girard F, Cravoisy A, Dousset B, Nace L, Levy B, Bollaert PE. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388-392.
14. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-1045.
15. Schenarts CL, March JA. Corticosteroids for patients with septic shock. JAMA 2003; 289:41-42.
16. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984; 39:973-981.
17. Neumann R, Worek FS et al. Cortisol deficiency in etomidate anesthetized bacteremic pigs: results in circulatory failure - beneficial effect of cortisol substitution. Acta Anaesthesiol Scand 1989; 33:379-384.
18. Annane D. ICU physicians should abandon the use of etomi-date! Intensive Care Med 2005; 31:325-326.
19. Annane D, Aegerter P, Jars-Guincestre M, Guidet B for the CUB-Réa Network Current Epidemiology of Septic Shock. The CUB-Réa Network. Am J Respir Crit Care Med 2003; 168:165-172.
20. Bernard GR, Vincent JL, Laterre PF et al. Recombinant human protein C Worldwide Evaluation in Severe. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
21. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30:589-596.